Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
US9155745B2 · kind B2 · utility
1Cited by
0References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 9, 2010 |
| Grant date | Oct 13, 2015 |
| Priority date | — |
| Expiry date | Sep 17, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to combination formulations of monoclonal antibodies with anti-inflammatory agents, related methods and uses thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.